Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 15/100

Failure Rate

0.0%

0 terminated/withdrawn out of 13 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

62%

8 trials in Phase 3/4

Results Transparency

54%

7 of 13 completed trials have results

Key Signals

7 with results

Enrollment Performance

Analytics

Phase 3

7(53.8%)

Phase 2

3(23.1%)

Phase 1

2(15.4%)

Phase 4

1(7.7%)

13Total

Phase 3(7)

Phase 2(3)

Phase 1(2)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (13)

Showing 13 of 13 trials

NCT04094025Phase 1Completed

Irritation and Sensitization Study of d-Amphetamine Transdermal System

Role: lead

NCT00434213Phase 4Completed

Characterization of Dermal Reactions in Pediatric Patients With ADHD Using DAYTRANA

Role: lead

NCT00499863Phase 3Completed

Evaluate the Efficacy &Safety of Methylphenidate Transdermal System (MTS) in Adolescents Aged 13-17 Years With ADHD

Role: lead

NCT00501293Phase 3Completed

Evaluate the Safety and Efficacy of Methylphenidate Transdermal System (MTS) in Adolescents Aged 13-17 Years With ADHD

Role: lead

NCT00151957Phase 3Completed

Safety and Tolerability of SPD485 in Children Aged 6-12 Diagnosed With ADHD and Previously Participated in MTS Trials

Role: lead

NCT01361308Phase 3Completed

Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS)

Role: lead

NCT01101841Phase 3Completed

24-Week Efficacy & Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms

Role: lead

NCT00786188Phase 2Completed

Eight-Week Efficacy & Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms Associated With Menopause

Role: lead

NCT01829919Phase 1Completed

Pharmacokinetic Evaluation of Brisdelle™ (Formerly Known as Mesafem) Following Single & Repeat Oral Administration in Healthy Postmenopausal Women

Role: lead

NCT00151983Phase 3Completed

Safety & Tolerability of MTS in Children Aged 6-12 Diagnosed With ADHD & Previously Treated With Extended-Release Methylphenidate Therapy

Role: lead

NCT00151970Phase 2Completed

Efficacy, Safety and Tolerability of SPD485 in Children Aged 6-12 Diagnosed With ADHD

Role: lead

NCT00444574Phase 3Completed

Safety and Efficacy of MTS Versus Concerta in Pediatric Patients (Aged 6-12 Years) With ADHD

Role: lead

NCT00466791Phase 2Completed

Classroom Study to Assess Efficacy and Safety of MTS in Pediatric Patients Aged 6-12 With ADHD

Role: lead

All 13 trials loaded